{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:22:24Z","timestamp":1778080944687,"version":"3.51.4"},"reference-count":63,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"\n Importance<\/jats:title>\n Health plan disenrollment may interrupt treatment for opioid use disorder (OUD) and overall care, increasing risk for serious outcomes, including overdose and death. There is limited evidence on the association of disenrollment with all-cause and overdose mortality after initiating medications for OUD (MOUD) treatment.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the association of health plan disenrollment with all-cause and overdose mortality in patients treated with MOUD.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study included privately and publicly insured patients aged 16 years or older who initiated buprenorphine or naltrexone for OUD treatment between January 1, 2012, and December 31, 2021, at 3 integrated health insurance and care delivery systems in 2 US states. Patients were followed up to 2 years until December 31, 2022. Data were analyzed July 2024 to November 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Health plan disenrollment following MOUD initiation.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n All-cause mortality and drug-related and alcohol-related overdose mortality within 2 years of MOUD initiation ascertained from the National Death Index. Survival analyses were adjusted for patient sociodemographic and clinical characteristics.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 20\u202f011 patients (mean [SD] age 38.7 [15.1] years; 12\u202f299 males [61.5%]) who were treated for OUD, 6948 (34.7%) experienced disenrollment and 586 (2.9%) died during follow-up. The crude rate was 15.3 (95% CI, 14.1-16.6) per 1000 person-years for all-cause mortality and 6.2 (95% CI, 5.4-7.0) per 1000 person-years for overdose mortality. Ever experiencing disenrollment showed elevated all-cause mortality (17.6 [95% CI, 14.9-20.8] vs 14.7 [95% CI, 13.4-16.1] per 1000 person-years) and overdose mortality (8.9 [95% CI, 7.1-11.3] vs 5.4 [95% CI, 4.7-6.3] per 1000 person-years) relative to remaining enrolled. In adjusted analyses, ever experiencing disenrollment was associated with increased hazards of all-cause (hazard ratio [HR], 1.51; 95% CI, 1.23-1.84) and overdose mortality (HR, 1.56; 95% CI, 1.17-2.09). Compared with remaining enrolled and receiving MOUD treatment, being disenrolled (HR, 4.34; 95% CI, 3.19-5.89) and being enrolled and not receiving MOUD treatment (HR, 4.19; 95% CI, 3.24-5.43) were associated with overall mortality.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients who initiated MOUD, experiencing health plan disenrollment was associated with increased mortality risk compared with remaining enrolled. Strategies are needed to improve continuity of health coverage and mitigate the elevated mortality risk during insurance transitions for patients receiving medications for OUD.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2026.0021","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:30:42Z","timestamp":1772641842000},"page":"491","source":"Crossref","is-referenced-by-count":0,"title":["Health Plan Disenrollment and Mortality After Initiation of Medications for Opioid Use Disorder"],"prefix":"10.1001","volume":"83","author":[{"given":"Anh P.","family":"Nguyen","sequence":"first","affiliation":[{"name":"Institute for Health Research, Kaiser Permanente Colorado, Aurora"},{"name":"Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid A.","family":"Binswanger","sequence":"additional","affiliation":[{"name":"Institute for Health Research, Kaiser Permanente Colorado, Aurora"},{"name":"Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California"},{"name":"Colorado Permanente Medical Group, Denver"},{"name":"Division of General Internal Medicine, University of Colorado School of Medicine, Aurora"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komal J.","family":"Narwaney","sequence":"additional","affiliation":[{"name":"Institute for Health Research, Kaiser Permanente Colorado, Aurora"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Goodrich","sequence":"additional","affiliation":[{"name":"Institute for Health Research, Kaiser Permanente Colorado, Aurora"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Christine","sequence":"additional","affiliation":[{"name":"Institute for Health Research, Kaiser Permanente Colorado, Aurora"},{"name":"Division of General Internal Medicine, University of Colorado School of Medicine, Aurora"},{"name":"Department of General Internal Medicine, Denver Health and Hospital Authority, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia I.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California"},{"name":"Division of Research, Kaiser Permanente Northern California, Pleasanton"},{"name":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California"},{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy M.","family":"Loree","sequence":"additional","affiliation":[{"name":"Center for Health Policy & Health Services Research, Henry Ford Health, Detroit, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason M.","family":"Glanz","sequence":"additional","affiliation":[{"name":"Institute for Health Research, Kaiser Permanente Colorado, Aurora"},{"name":"Department of Epidemiology, Colorado School of Public Health, Aurora"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"6","key":"yoi260002r1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1056\/NEJMsb1706645","article-title":"Health insurance coverage and health\u2014what the recent evidence tells us.","volume":"377","author":"Sommers","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"yoi260002r2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2222100120","article-title":"The risk of losing health insurance in the United States is large, and remained so after the Affordable Care Act.","volume":"120","author":"Einav","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"yoi260002r3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1377\/hlthaff.2016.0455","article-title":"Insurance churning rates for low-income adults under health reform: lower than expected but still harmful for many.","volume":"35","author":"Sommers","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"3","key":"yoi260002r4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/09514848221146677","article-title":"A conceptual model of health insurance stability in the United States health care system.","volume":"36","author":"Grembowski","year":"2023","journal-title":"Health Serv Manage Res"},{"issue":"1","key":"yoi260002r5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12913-020-05226-1","article-title":"Insurance patterns and instability from 2006 to 2016.","volume":"20","author":"Gai","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"8","key":"yoi260002r6","doi-asserted-by":"publisher","first-page":"e232717","DOI":"10.1001\/jamahealthforum.2023.2717","article-title":"Trends in cumulative disenrollment in the Medicare Advantage Program, 2011-2020.","volume":"4","author":"Meyers","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"2","key":"yoi260002r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0320","article-title":"Trends in disenrollment and reenrollment within US commercial health insurance plans, 2006-2018.","volume":"5","author":"Fang","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"yoi260002r8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/1472-6963-10-195","article-title":"Impact of discontinuity in health insurance on resource utilization.","volume":"10","author":"Banerjee","year":"2010","journal-title":"BMC Health Serv Res"},{"issue":"10","key":"yoi260002r9","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s11606-017-4072-4","article-title":"Insurance transitions and changes in physician and emergency department utilization: an observational study.","volume":"32","author":"Barnett","year":"2017","journal-title":"J Gen Intern Med"},{"issue":"5","key":"yoi260002r10","doi-asserted-by":"publisher","first-page":"e1026","DOI":"10.1542\/peds.2006-2747","article-title":"Impact of Medicaid disenrollment on health care use and cost.","volume":"119","author":"Rimsza","year":"2007","journal-title":"Pediatrics"},{"issue":"1","key":"yoi260002r11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder.","volume":"6","author":"Strang","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"20","key":"yoi260002r12","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1001\/jama.2019.16932","article-title":"Life expectancy and mortality rates in the United States, 1959-2017.","volume":"322","author":"Woolf","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"yoi260002r13","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1097\/ADM.0000000000000606","article-title":"Mortality among people with opioid use disorder: a systematic review and meta-analysis.","volume":"14","author":"Bahji","year":"2020","journal-title":"J Addict Med"},{"issue":"4","key":"yoi260002r14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/ADM.0000000000000312","article-title":"High mortality among patients with opioid use disorder in a large healthcare system.","volume":"11","author":"Hser","year":"2017","journal-title":"J Addict Med"},{"issue":"9","key":"yoi260002r15","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis.","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"yoi260002r16","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"yoi260002r17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"key":"yoi260002r18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.","volume":"200","author":"Morgan","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"yoi260002r19","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab289","article-title":"A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes.","volume":"8","author":"McNamara","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"yoi260002r20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5945","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis.","volume":"345","author":"MacArthur","year":"2012","journal-title":"BMJ"},{"key":"yoi260002r21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.drugalcdep.2015.10.009","article-title":"Short term health-related quality of life improvement during opioid agonist treatment.","volume":"157","author":"Nosyk","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"yoi260002r22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: a review.","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yoi260002r23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/add.15998","article-title":"The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment.","volume":"118","author":"Glanz","year":"2023","journal-title":"Addiction"},{"issue":"12","key":"yoi260002r24","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1111\/add.15959","article-title":"Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.","volume":"117","author":"Burns","year":"2022","journal-title":"Addiction"},{"key":"yoi260002r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108329","article-title":"Who stays in medication treatment for opioid use disorder? a national study of outpatient specialty treatment settings.","volume":"126","author":"Krawczyk","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"yoi260002r26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review.","volume":"35","author":"Timko","year":"2016","journal-title":"J Addict Dis"},{"issue":"12","key":"yoi260002r27","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamapsychiatry.2022.3118","article-title":"Association between buprenorphine treatment gaps, opioid overdose, and health care spending in US Medicare beneficiaries with opioid use disorder.","volume":"79","author":"Gibbons","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"yoi260002r28","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.2014","article-title":"Insurance instability for patients with opioid use disorder in the year after diagnosis.","volume":"5","author":"Christine","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"11","key":"yoi260002r29","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1007\/s11606-021-07344-w","article-title":"Mortality among patients prescribed buprenorphine for opioid use disorder after disenrollment from an insurance plan and healthcare system.","volume":"37","author":"Nguyen","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"9596","key":"yoi260002r31","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"yoi260002r32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41380-020-00949-3","article-title":"Polysubstance use in the U.S. opioid crisis.","volume":"26","author":"Compton","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"6","key":"yoi260002r33","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s11524-006-9094-x","article-title":"The development of a standardized neighborhood deprivation index.","volume":"83","author":"Messer","year":"2006","journal-title":"J Urban Health"},{"issue":"6","key":"yoi260002r34","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"yoi260002r35","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"11","key":"yoi260002r38","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1093\/ndt\/gft355","article-title":"When do we need competing risks methods for survival analysis in nephrology?","volume":"28","author":"Noordzij","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"yoi260002r39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder.","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"13","key":"yoi260002r40","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders.","volume":"374","author":"Lee","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"yoi260002r41","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1176\/appi.ps.201700363","article-title":"Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults.","volume":"69","author":"Manhapra","year":"2018","journal-title":"Psychiatr Serv"},{"issue":"5","key":"yoi260002r42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.8469","article-title":"Medicaid unwinding and changes in buprenorphine dispensing.","volume":"8","author":"Constantin","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1-3","key":"yoi260002r43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.drugalcdep.2007.11.018","article-title":"Opioid use disorder in the United States: insurance status and treatment access.","volume":"94","author":"Becker","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"yoi260002r44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders.","volume":"19","author":"Sharma","year":"2017","journal-title":"Curr Psychiatry Rep"},{"issue":"1","key":"yoi260002r45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11414-016-9538-3","article-title":"Reasons for not seeking substance use disorder treatment: variations by health insurance coverage.","volume":"44","author":"Ali","year":"2017","journal-title":"J Behav Health Serv Res"},{"issue":"6","key":"yoi260002r46","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/add.12863","article-title":"Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10.","volume":"110","author":"Evans","year":"2015","journal-title":"Addiction"},{"issue":"1","key":"yoi260002r47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1377\/hlthaff.2019.00378","article-title":"Among low-income adults enrolled in Medicaid, churning decreased after the Affordable Care Act.","volume":"39","author":"Goldman","year":"2020","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"yoi260002r48","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/1475-6773.13861","article-title":"Patient administrative burden in the US health care system.","volume":"56","author":"Kyle","year":"2021","journal-title":"Health Serv Res"},{"issue":"2","key":"yoi260002r49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder.","volume":"177","author":"Williams","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"5","key":"yoi260002r50","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid.","volume":"39","author":"Samples","year":"2020","journal-title":"Health Aff (Millwood)"},{"key":"yoi260002r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2024.102832","article-title":"Association of chronic opioid therapy and opioid use disorder with COVID-19-related hospitalization and mortality: Evidence from three health systems in the United States.","volume":"46","author":"Nguyen","year":"2024","journal-title":"Prev Med Rep"},{"issue":"2","key":"yoi260002r52","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2105\/AJPH.2017.304187","article-title":"Opioid crisis: no easy fix to its social and economic determinants.","volume":"108","author":"Dasgupta","year":"2018","journal-title":"Am J Public Health"},{"issue":"1","key":"yoi260002r53","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev-publhealth-032013-182500","article-title":"Precarious employment: understanding an emerging social determinant of health.","volume":"35","author":"Benach","year":"2014","journal-title":"Annu Rev Public Health"},{"issue":"11","key":"yoi260002r54","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.4258","article-title":"Association of health insurance coverage disruptions with mortality risk among US working-age adults.","volume":"3","author":"Yabroff","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"5","key":"yoi260002r58","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.0839","article-title":"Loss of Medicaid coverage during the renewal process.","volume":"5","author":"Dague","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"11","key":"yoi260002r59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2501855","article-title":"Medicaid on the chopping block.","volume":"393","author":"Park","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"yoi260002r60","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.7326\/ANNALS-25-00716","article-title":"Projected effects of proposed cuts in federal Medicaid expenditures on Medicaid enrollment, uninsurance, health care, and health.","volume":"178","author":"Gaffney","year":"2025","journal-title":"Ann Intern Med"},{"issue":"15","key":"yoi260002r63","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMp2210121","article-title":"Transforming management of opioid use disorder with universal treatment.","volume":"387","author":"Gupta","year":"2022","journal-title":"N Engl J Med"},{"key":"yoi260002r37","doi-asserted-by":"crossref","DOI":"10.1002\/9780470258019","volume-title":"Applied Survival Analysis: Regression Modeling of Time-to-Event Data","author":"Hosmer","year":"2008"},{"key":"yoi260002r30","unstructured":"National Death Index User\u2019s Guide. National Center for Health Statistics; US Centers for Disease Control and Prevention. Accessed May 12, 2025. https:\/\/www.cdc.gov\/nchs\/data\/ndi\/2024-NDI-User-Guide.pdf"},{"key":"yoi260002r36","unstructured":"Quality Improvement and Care Coordination: Implementing the CDC Guideline for Prescribing Opioids for Chronic Pain. National Center for Injury Prevention and Control, Division of Unintentional Injury Prevention. Accessed October 2023. https:\/\/stacks.cdc.gov\/view\/cdc\/59082"},{"key":"yoi260002r55","unstructured":"Pollitz? K, Rae? M, Cox? C, Kamal? R, Fehr? R, Young G. Key issues related to COBRA subsidies. KFF. May 28, 2020. Accessed May 5, 2025. https:\/\/www.kff.org\/private-insurance\/issue-brief\/key-issues-related-to-cobra-subsidies\/"},{"key":"yoi260002r56","unstructured":"Saunders? H, Rudowitz? R. Implications of potential federal Medicaid reductions for addressing the opioid epidemic. KFF. May 14, 2025. Accessed October 21, 2025. https:\/\/www.kff.org\/medicaid\/implications-of-potential-federal-medicaid-reductions-for-addressing-the-opioid-epidemic\/"},{"key":"yoi260002r57","unstructured":"Donohue? J, Cunningham? P, Walker? L, Garfield? R. Opioid use disorder among Medicaid enrollees: snapshot of the epidemic and state responses. KFF. November 15, 2019. Accessed October 21, 2025. https:\/\/www.kff.org\/medicaid\/opioid-use-disorder-among-medicaid-enrollees-snapshot-of-the-epidemic-and-state-responses\/"},{"key":"yoi260002r61","unstructured":"Ortaliza? J, Cord? A, McGough? M, Lo? J, Cox? C. Inflation Reduction Act health insurance subsidies: what is their impact and what would happen if they expire? KFF. July 26, 2024. Accessed May 6, 2025. https:\/\/www.kff.org\/affordable-care-act\/issue-brief\/inflation-reduction-act-health-insurance-subsidies-what-is-their-impact-and-what-would-happen-if-they-expire\/"},{"key":"yoi260002r62","unstructured":"McGough? M, Ortaliza? J, Cotter? L, Cox? C. Early indications of the impact of the enhanced premium tax credit expiration on 2026 Marketplace premiums. Peterson-KFF Health System Tracker. June 3, 2025. Accessed November 7, 2025. https:\/\/www.healthsystemtracker.org\/brief\/early-indications-of-the-impact-of-the-enhanced-premium-tax-credit-expiration-on-2026-marketplace-premiums\/"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2845753\/jamapsychiatry_nguyen_2026_oi_260002_1777052921.03797.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:00:41Z","timestamp":1778079641000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2845753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.0021","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}